Shop Antibodies

Adalimumab Biosimilar Antibody

$205.00$2,500.00

Item Cat No.: BS0001

Antibody: Monoclonal Antibody

Concentration: 0.50 mg/ml

Application: In vitro and In vivo

Reactivity: Human

Adalimumab is a humanized immunoglobulin (Ig) G1-kappa monoclonal antibody against human tumor necrosis factor-alpha (TNFα) protein.

Adalimumab, sold under the brand name Humira, is a monoclonal anti-tumor necrosis factor alpha antibody used in the treatment of a wide variety of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ankylosing spondylitis.

TNF is a naturally occurring cytokine that plays a role in normal inflammatory and immune responses. Increased levels of TNF are found in the joint synovial fluid of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis patients, and play an imperative role in pathologic inflammation and joint destruction that are major complications of these diseases. Adalimumab binds with specificity to tumor necrosis factor-alpha and inhibits its interaction with the p55 and p75 cell surface TNF receptors.

Host/Isotype: Human/IgG1

Class: Monoclonal

Immunogen: Human TNFα protein

Production platform: CHO cells

Purification: Affinity chromatography

Storage buffer: PBS, pH 7.2

Storage condition: –20°C


For Research Use Only. Not for use in clinical diagnostics or therapeutics.

Additional information

Antibody Production Scale

50 ug, 250 ug, 1 mg

Conjugate

None, FITC, HRP, ADC (custom drug)

Reviews

There are no reviews yet.

Be the first to review “Adalimumab Biosimilar Antibody”

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

"The rabbit hybridoma supernatants of anti-APOBEC3 project are tested positive by ELISA, and we are very happy about it! We previously tried a company, Abclone. Their Project "A" has immune response that is <10,000 titer in antiserum, which would explain why there is no positive mAb after fusion. Their project "B" didn't have any immune response in rabbit."

Harshita B Gupta, PhD.

School of Medicine | UT Health San Antonio

Contact us for questions or custom requests!